These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 865760)

  • 1. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
    Wittes RE; Hong WK; Gatchell L; Krakoff IH; Golbey RB
    Oncology; 1977; 34(1):45-6. PubMed ID: 865760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Creagan ET; Ahmann DL; Schutt AJ; Green SJ
    Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; Eagan RT; O'Connell MJ; Frytak S
    Clin Pharmacol Ther; 1976 Jun; 19(6):821-4. PubMed ID: 773589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
    Belt RJ; Stephens R
    Cancer; 1979 Sep; 44(3):869-72. PubMed ID: 383275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
    Cohen MH; Schoenfeld D; Wolter J
    Cancer Treat Rep; 1980 Jan; 64(1):151-3. PubMed ID: 6991102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
    Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
    [No Abstract]   [Full Text] [Related]  

  • 7. Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
    Micetich KC; Jensen-Akula M; Mandard JC; Fisher RI
    Am J Med; 1981 Dec; 71(6):967-72. PubMed ID: 7032289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of very high dose nitrosourea administration.
    Breeden JH; Vollmer JT; Twomey PL
    Cancer; 1982 Nov; 50(9):1728-33. PubMed ID: 7116300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
    Lee W; Moore RP; Wampler GL
    Cancer Treat Rep; 1978 Sep; 62(9):1355-8. PubMed ID: 688278
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized comparison of two dosage schedules of methyl CCNU: three-week versus six-week treatments.
    Taylor SG; DeWys WD; Perlia CP; Wolter J; Slayton RE; Kosova LA; Khandekar JD
    Cancer; 1979 Sep; 44(3):824-30. PubMed ID: 383272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
    Tornyos K; Silberman H; Solomon A
    Cancer Treat Rep; 1977 Aug; 61(5):785-7. PubMed ID: 329977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.
    Buroker T; Kim PN; Groppe C; McCracken J; O'Bryan R; Panettiere F; Coltman C; Bottomley R; Wilson H; Bonnet J; Thigpen T; Vaitkevicius VK; Hoogstraten B; Heilbrun L
    Cancer; 1978 Sep; 42(3):1228-33. PubMed ID: 359121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
    Kane RC; Cashdollar MR; Bernath AM
    Cancer Treat Rep; 1978 Oct; 62(10):1521-5. PubMed ID: 709554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults.
    Yap BS; Benjamin RS; Burgess MA; Murphy WK; Sinkovics JG; Bodey GP
    Cancer; 1981 Jun; 47(12):2807-9. PubMed ID: 7260872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
    White LA; Perry MC; Kardinal CG; Kennedy BJ; Weiss RB; Carey RW
    Cancer Treat Rep; 1979 Feb; 63(2):215-7. PubMed ID: 445497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of intravenously- administered methyl CCNU in the treatment of advanced sarcomas.
    Chang P; Levine MA; Wiernik PH; Walker MD
    Cancer; 1976 Feb; 37(2):615-9. PubMed ID: 766946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of semustine in a weekly schedule.
    Koller CA; Schwalm D; Liepman M; Natale RB; Wheeler RH
    Cancer Treat Rep; 1983 Jun; 67(6):579-81. PubMed ID: 6861164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
    Kokoschka EM; Luger T; Micksche M
    Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.